Aurinia Pharmaceuticals (AUPH) Assets (2016 - 2026)

Aurinia Pharmaceuticals' Assets history runs 11 years deep, the most recent figure standing at $724.0 million for Q1 2026.

• Quarterly Assets rose 43.41% year-over-year to $724.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $724.0 million (up 43.41% YoY) and the FY2025 annual result came in at $751.6 million, up 36.49% from the prior year.
• Assets was $724.0 million for Q1 2026 at Aurinia Pharmaceuticals, down from $751.6 million in the prior quarter.
• Across five years, Assets topped out at $751.6 million in Q4 2025 and bottomed at $451.8 million in Q1 2023.
• A 5-year average of $541.3 million and a median of $523.5 million in 2024 frame the typical range for Assets.
• Annual changes were most pronounced in 2022 — Assets retreated 13.34% — and 2026, when it soared 43.41%.
• Aurinia Pharmaceuticals' Assets stood at $470.9 million in 2022, then increased by 16.4% to $548.1 million in 2023, then grew by 0.47% to $550.6 million in 2024, then soared by 36.49% to $751.6 million in 2025, then slipped by 3.67% to $724.0 million in 2026.
• Business Quant data shows AUPH's Assets at $724.0 million in Q1 2026, $751.6 million in Q4 2025, and $527.5 million in Q3 2025.